Primary Membranous Nephropathy (PMN) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Primary Membranous Nephropathy (PMN) Emerging Therapy and TPP Insights Thelansis’s “Primary Membranous Nephropathy (PMN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Primary Membranous Nephropathy (PMN) Overview Primary Membranous Nephropathy (PMN) is a specific, autoimmune-mediated glomerular disease that serves as one of the leading causes of nephrotic syndrome in non-diabetic adults. Clinically, it manifests with massive proteinuria (>3.5 g/day), profound peripheral edema, hypoalbuminemia, hyperlipidemia, and a significantly elevated risk of thromboembolic events, such as renal vein thrombosis. The pathophysiology is defined by the subepithelial deposition of IgG4 autoantibodies and complement complexes (specifically t...